News | Hypertension | September 10, 2015

Sunshine Heart Initiates C-Pulse Animal Study for Pulmonary Arterial Hypertension Treatment

If successful, technology would offer therapeutic options for patient population that currently has no approved treatments

September 10, 2015 — Sunshine Heart Inc. announced commencement of a new study examining the impact of the C-Pulse system on pulmonary circulation and right heart related to pulmonary hypertension and heart failure. The study is a collaborative effort with Mark Slaughter, M.D., and the University of Louisville.

Pulmonary arterial hypertension (PAH) is a debilitating condition characterized by progressive increases in pulmonary vascular resistance and loss of elasticity of the pulmonary artery and large vessels. Patients with PAH suffer from poor quality of life, shortness of breath and greatly reduced functional capacity leading to right ventricular dysfunction and ultimately, right heart failure. PAH afflicts approximately 200,000 patients worldwide and places a significant burden on the healthcare system, with limited treatment options available and five-year survival rates as low as 34 percent. PAH and right heart failure are also commonly associated with left heart failure. Approximately 50 percent of patients with systolic heart failure or preserved ejection fraction heart failure (HFpEF) have PAH with similar five-year outcomes. PAH and right heart failure also continue to remain a significant risk in the left ventricular assist device patient population.

These studies hope to provide scientific rationale for a new application of current C-Pulse therapy by leveraging the existing technology to apply counterpulsation to the pulmonary artery in acute and chronic animal preparations. Biochemical, neurohormonal, and pressure-volume data will be used to assess the effects of C-Pulse on pulmonary circulation and right and left heart properties. A fully implantable system may provide therapeutic options in HFpEF populations with PAH where there are currently no approved treatments.

For more information: www.sunshineheart.com


Additional Content

News | Hypertension

Oct. 22, 2026 — Henry Ford Health has performed the first procedures globally in a clinical trial evaluating pulmonary ...

Home October 23, 2026
Home
News | Hypertension

July 16, 2025 — Insmed Inc. recently announced positive 12-Month data from the ongoing open-label extension (OLE) study ...

Home July 20, 2026
Home
News | Hypertension

July 9, 2026 — A new artificial intelligence (AI) clinical tool developed by researchers at the University of Maryland ...

Home July 09, 2026
Home
News | Hypertension

May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the U.S. as a first-in-class aldosterone ...

Home May 18, 2026
Home
News | Hypertension

Sept. 04, 2025 — CorVista Health has published a new case series in the Journal of the American College of Cardiology ...

Home September 09, 2025
Home
Subscribe Now